# Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lun

Source: https://onco.cc/trials/nct03811002/  
OnCo record `nct03811002` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of atezolizumab, carboplatin, cisplatin and etoposide in lung cancer, run by National Cancer Institute (NCI), active but no longer recruiting.

## Summary

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) is a phase 3, randomised interventional study registered as NCT03811002 by National Cancer Institute (NCI), with a registry enrolment figure of 544 participants, started 2019-07-26 and due to reach its primary completion in 2024-04-21. Interventions recorded: 3-Dimensional Conformal Radiation Therapy; Atezolizumab; Biospecimen Collection; Carboplatin; Cisplatin; Etoposide; Intensity-Modulated Radiation Therapy; Quality-of-Life Assessment; Questionnaire Administration. Conditions listed: Limited Stage Lung Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8. Primary outcome: Overall Survival. Lung eligibility wording from the registry: "* Pathologically (histologically or cytologically) proven diagnosis of limited stage small cell lung cancer (Stage Tx, T1-T4, N0-3, M0, American Joint Committee on Cancer \[AJCC\] staging, 8th edition \[Ed". Sites: Japan, United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT03811002
- Phase: 3
- Setting: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 544

## Sources

- ClinicalTrials.gov NCT03811002: https://clinicaltrials.gov/study/NCT03811002

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Etoposide](https://onco.cc/drugs/etoposide/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03811002.json